Invion Reaches Key Milestone in Phase I/II Non-Melanoma Skin Cancer Trial.

Invion Limited (ASX: IVX) has successfully completed dosing the first six patients in its Phase I/II clinical trial targeting non-melanoma skin cancer (NMSC) using topical INV043. This milestone activates a scheduled review by the Safety Review Committee (SRC), which will assess patient safety data and consider potential adjustments to the trial’s next phase, including dose-light intervals or expanding the study to include superficial basal cell carcinoma (sBCC).

The six patients were treated at two Queensland sites—Veracity Clinical Research and the recently added Cornerstone Dermatology—as part of a light dose escalation study, maintaining a constant dose of INV043. This trial evaluates the safety and efficacy of INV043, an Australian-developed photosensitiser used in Photodynamic Therapy (PDT). With NMSC accounting for over 98% of all skin cancer cases and a projected global treatment market value of US$21.1 billion by 2032, Invion’s progress highlights its growing role in addressing a widespread medical challenge.

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com